At 8.4% CAGR, the Europe Dental Bone Graft Substitute and Barrier Membrane Market is projected to be worth US$ 517.88 million by 2030, says Business Market Insights

According to Business Market Insights research, the Europe dental bone graft substitute and barrier membrane market was valued at US$ 271.56 million in 2022 and is expected to reach US$ 517.88 million by 2030, registering a CAGR of 8.4% from 2022 to 2030. Increasing burden of periodontal diseases and oral cancer, strategic developments by market players are the critical factors attributed to the Europe dental bone graft substitute and barrier membrane market expansion.

Development strategies such as product launches, mergers and acquisitions, and expansions boost the growth of the Europe Dental Bone Graft Substitute and Barrier Membrane Market. In April 2023, ZimVie announced the launch of RegenerOss CC Allograft Particulate and RegenerOss Bone Graft Plug, which helped it extend its portfolio of biomaterials that are intended for filling extraction sockets and periodontal defects. In May 2023, Straumann acquired GalvoSurge Dental AG, a Swiss medical device manufacturer. The acquired company specializes in implant care and maintenance solutions to support the treatment of peri-implantitis. The acquisition helped Geistlich Pharma to strengthen its portfolio by adding Lynch Biologics, LLC's leading GEM 21S product to it. GEM 21S is based on a growth factor that accelerates bone formation and wound healing. The companies further aim to innovate regenerative technologies in dentistry. In December 2022, Neoss Group, which designs, manufactures, and sells dental implant treatment products, opened a new sales office in the Nordic region. The facility commenced operations in the Nordic region on December 01, 2022, to support dental professionals and their patients. In January 2021, Dentsply Sirona acquired Datum Dental, a leading provider of innovative OSSIX regenerative solutions. The acquisition enabled Dentsply Sirona to acquire the strong OSSIX biomaterial portfolio of Datum Dental, Ltd. It also offered it access to the patented GLYMATRIX technology of Datum Dental Ltd. GLYMATRIX mimics the natural collagen cycle in the body, i.e., a biochemical process called glycation. GLYMATRIX forms the basis of OSSIX products for guided bone regeneration, as well as guided tissue regeneration.

On the contrary, high cost of products & procedures and delays in dental check-ups hampers the Europe dental bone graft substitute and barrier membrane market.  

Based on product, the Europe dental bone graft substitute and barrier membrane market has been bifurcated into dental bone graft substitutes and dental barrier membranes. The dental bone graft substitutes segment held 77.1% share of Europe dental bone graft substitute and barrier membrane market in 2022, amassing US$ 209.36 million. It is projected to garner US$ 392.64 million by 2030 to expand at 8.2% CAGR during 2022–2030.

Based on procedures, the Europe dental bone graft substitute and barrier membrane market is segmented into guided bone regeneration (GBR) procedures, guided tissue regeneration (GTR) procedures, sinus-lift and ridge-split procedures, alveolar ridge preservation (ARP), block-graft procedures, periodontal regeneration procedures, socket preservation, and others. The sinus-lift and ridge-split procedures segment held 23.8% share of Europe dental bone graft substitute and barrier membrane market in 2022, amassing US$ 64.71 million. It is projected to garner US$ 123.26 million by 2030 to expand at 8.4% CAGR during 2022–2030.

Based on end user, the Europe dental bone graft substitute and barrier membrane market is segmented into hospitals, dental clinics, and others. The dental clinics procedures segment held 69.9% share of Europe dental bone graft substitute and barrier membrane market in 2022, amassing US$ 189.77 million. It is projected to garner US$ 373.83 million by 2030 to expand at 8.8% CAGR during 2022–2030.

Based on country, the Europe dental bone graft substitute and barrier membrane market has been categorized into the U.K., Germany, France, Italy, Spain, and Rest of Europe. Our regional analysis states that a Germany captured 29.5% share of Europe Dental Bone Graft Substitute and Barrier Membrane Market in 2022. It was assessed at US$ 79.97 million in 2022 and is likely to hit US$ 147.96 million by 2030, exhibiting a CAGR of 8.0% during the 2022-2030.

Key players operating in the Europe Dental Bone Graft Substitute and Barrier Membrane Market are Geistlich Pharma AG, Medtronic Plc, Dentsply Sirona Inc, Matricel GmbH, ZimVie Inc, Regenity Biosciences Inc, Neoss UK & Ireland Ltd, Institut Straumann AG, CAMLOG Biotechnologies GmbH and Resorba Medical GmbH.

• Geistlich acquired Lynch Biologics in the USA. The acquisition helped Geistlich Pharma to strength its portfolio adding Lynch Biologics, LLC's leading product GEM 21S, which is based on a growth factor that accelerates bone formation and wound healing. The companies have aimed to advance new regenerative technologies in dentistry. 
• Geistlich Pharma acquired the medical technology company Meta Technologies S.r.l. With the acquisition of Meta Technologies S.r.l., Geistlich Pharma is expanding its existing offering as a regeneration specialist by adding a further recognized brand. Meta Technologies S.r.l. will continue its business relationships independently.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com